Back to results
US 12,516,093 B2Granted
Recombinant erIL-15 NK cells
AssigneesImmunityBio, Inc., NantBio, Inc., NantCell, Inc.
InventorsPatrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi, Hans G. Klingemann
Life of this patent
Estimating the term…
Abstract
Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.
Claims15
A method of treatment for cancer, the method comprising administering to a patient in need thereof a genetically modified NK cell comprising a recombinant nucleic acid that encodes erLSP-IL-15 according to SEQ ID NO:5.
Dependencies are inferred from the claim text.